Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The U.S. Food and Drug Administration said on Wednesday it will hold a meeting of experts on May 22 to discuss COVID-19 ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

By Akin Nazli in Belgrade Ugur Sahin, owner of BioNTech (Nasdaq/BNTX), has been ranked second in Forbes Turkey’s Top 100 ...

Clinical trials are the cornerstone of medical innovation, offering a rigorous framework to evaluate the safety and ...

Scientists project that by 2026 the results of clinical trials being conducted in 25 countries, including Spain, will be ...

When the smoke cleared, BioNTech's shares closed the day more than 6% lower. The Food and Drug Administration (FDA), a ...

The U.S. FDA has appointed Vinay Prasad to be the next director of its Center for Biologics Evaluation and Research division ...

Research teams across Canada are now building mRNA to expand the potential of RNA vaccines beyond infectious diseases.

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

In late April, Summit Therapeutics revealed interim OS data from HARMONi-2 for its PD-1/VEGF bispecific antibody, ivonescimab ...

See what we found for BioNTech in our free report. Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 24%. Looking ahead, revenue is forecast to ...